Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date Sort descending | Expire Date | Purpose |
|---|---|---|---|---|---|
| Engaging Survivors of Sexual Violence and Trafficking in HIV and Substance Use Disorder Services (R34 Clinical Trial Optional) | RFA-DA-25-018 | NIDA | The goal of this concept is to support exploratory research and preliminary interventions to address the interrelated and compounding contextual factors that contribute to substance use and HIV risk… More | ||
| Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33) | PA-23-263 | NIH | The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or… More | ||
| Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) | PAR-23-274 | NIA | The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline… More | ||
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) | PAR-23-279 | NCI | The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or… More | ||
| Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01) | PAR-24-027 | NIDA | The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, serum, and genomic DNA) and related research data on behaviors,… More | ||
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed) | PAR-23-280 | NCI | The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or… More | ||
| IDeA Clinical and Translational Research Development (CTR-D) Award (P20-Clinical Trial Optional) | PAR-23-257 | NIGMS | The purpose of the IDeA-CTR initiative is to expand the capacity for clinical and translational research in IDeA-eligible states/jurisdictions and to enhance the competitiveness of the… More | ||
| IDeA Clinical and Translational Research Network (CTR-N) Award (P50 - Clinical Trial Optional) | PAR-23-241 | NIGMS | The purpose of the IDeA-CTR initiative is to expand the capacity for clinical and translational research in IDeA-eligible states/jurisdictions and to enhance the competitiveness of the… More | ||
| Broadening Opportunities for Computational Genomics and Data Science Education (UE5 Clinical Trial Not Allowed) | RFA-HG-23-002 | NHGRI | The NIH Research Education Program (UE5) supports research education activities in the mission areas of the NIH. The overarching goal of this UE5 program is to support educational activities that… More | ||
| Initiative to Maximize Research Education in Genomics: Diversity Action Plan (R25 Clinical Trials Not Allowed) | PAR-22-268 | NHGRI | The purpose of this Notice is to alert the community that NHGRI plans to publish a Funding Opportunity Announcement (FOA) to transform NHGRIs Diversity Action Plan (R25 Clinical Trials Not Allowed)… More |